Three decades after his son Gunnar's cystic fibrosis diagnosis, former NFL quarterback Boomer Esiason reflects on medical breakthroughs and expanded access to life-extending therapies. Their advocacy has helped reshape the treatment landscape for a rare genetic disorder.
- Gunnar Esiason was diagnosed with cystic fibrosis in 1995, when life expectancy was limited to about 20 years.
- The number of people living with cystic fibrosis in the U.S. has more than doubled since 1995, reaching over 31,000.
- Trikafta, a breakthrough modulator therapy, is now available to approximately 90% of eligible patients in the U.S.
- Annual treatment costs for Trikafta exceed $300,000, creating financial strain for many families.
- Advocacy efforts led by Boomer Esiason have contributed to over $1 billion in cystic fibrosis research funding.
- Ongoing clinical trials are exploring next-generation gene-editing therapies with potential for curative outcomes.
In 1995, Boomer Esiason's world changed when his then-3-year-old son Gunnar was diagnosed with cystic fibrosis, a rare genetic disease that affects the lungs and digestive system. The diagnosis, which initially carried a life expectancy of just 20 years, became the catalyst for a decades-long advocacy effort spearheaded by Esiason and the Cystic Fibrosis Foundation. Their work has helped accelerate research and improve treatment access for patients across the United States. The journey has yielded measurable progress: the number of people living with cystic fibrosis in the U.S. has increased from approximately 15,000 in 1995 to over 31,000 today. Advances in modulator therapies—such as Trikafta, approved in 2019—have extended life expectancy for patients with a majority of genetic mutations associated with the disease. For Gunnar Esiason, now in his 30s, the treatment has enabled a near-normal quality of life, with regular physical activity and a career in media. While the medical advances are significant, challenges remain. Access to expensive therapies such as Trikafta, which costs around $300,000 annually, varies across states and insurance plans. Advocacy efforts continue to push for expanded coverage and reduced financial burdens on families. Esiason has also testified before Congress and worked with pharmaceutical companies to ensure fair pricing and broader availability. The personal story of Boomer and Gunnar Esiason has become a symbol of hope and persistence in rare disease advocacy. Their influence has contributed to the funding of over $1 billion in research since the late 1990s, spurring innovation in gene therapy and next-generation modulators currently in clinical trials.